HRP20201729T1 - Antitijela protiv aktivina a i njihova primjena - Google Patents
Antitijela protiv aktivina a i njihova primjena Download PDFInfo
- Publication number
- HRP20201729T1 HRP20201729T1 HRP20201729TT HRP20201729T HRP20201729T1 HR P20201729 T1 HRP20201729 T1 HR P20201729T1 HR P20201729T T HRP20201729T T HR P20201729TT HR P20201729 T HRP20201729 T HR P20201729T HR P20201729 T1 HRP20201729 T1 HR P20201729T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigen
- antibody
- binding fragment
- gdf8
- amino acid
- Prior art date
Links
- 239000000488 activin Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 3
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 108010023082 activin A Proteins 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (5)
1. Izolirano antitijelo ili njegov fragment koji se vezuje za antigen koje se specifično vezuje za aktivin A s konstantom ravnoteže disocijacije vezivanja (KD) manjom od 5 pM, opcionalno s KD-om manjom od 4 pM, izmjereno testom rezonancije površinskih plazmona pri temperaturi od 25 °C, naznačeno time, što antitijelo ili fragment koji se vezuje za antigen obuhvaća: HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domene koje imaju aminokiselinske sekvence SEQ ID NO: 164-166-168-148-150-152.
2. Izolirano antitijelo ili njegov fragment koji se vezuje za antigen prema patentnom zahtjevu 1, naznačeno time, što antitijelo ili fragment koji se vezuje za antigen uključuje: (a) HCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 162; i (b) LCVR koji ima aminokiselinsku sekvencu SEQ ID NO: 146.
3. Farmaceutski pripravak koji obuhvaća antitijelo ili fragment koji se vezuje za antigen prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 i farmaceutski prihvatljivi nosač ili razrjeđivač.
4. Farmaceutski pripravak prema patentnom zahtjevu 3, koji dodatno obuhvaća antagonist GDF8, opcionalno naznačen time, što je antagonist GDF8 odabran iz skupine koja se sastoji od fuzijskog proteina koji inhibira GDF8, anti-GDF8 antitijela i fragmenta anti-GDF8 antitijela koji se vezuje za antigen.
5. Antitijelo ili njegov fragment koji se vezuje za antigen prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 ili farmaceutski pripravak prema patentnom zahtjevu 3 ili patentnom zahtjevu 4 za primjenu u liječenju, sprječavanju ili ublažavanju bolesti ili poremećaja karakteriziranog smanjenjem mišićne mase ili snage, naznačeno time, što je bolest ili poremećaj karakteriziran smanjenjem mišićne mase ili snage odabran iz skupine koja se sastoji od sarkopenije, kaheksije, ozljede mišića, propadanja/atrofije mišića, raka, pretilosti, dijabetesa, artritisa, multiple skleroze, mišićne distrofije, amiotrofične lateralne skleroze, Parkinsonove bolesti, osteoporoze, osteoartritisa, osteopenije i metaboličkog sindroma.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859926P | 2013-07-30 | 2013-07-30 | |
| US201361864036P | 2013-08-09 | 2013-08-09 | |
| US201361911834P | 2013-12-04 | 2013-12-04 | |
| US201361913885P | 2013-12-09 | 2013-12-09 | |
| PCT/US2014/048957 WO2015017576A1 (en) | 2013-07-30 | 2014-07-30 | Anti-activin a antibodies and uses thereof |
| EP14750421.1A EP3027209B1 (en) | 2013-07-30 | 2014-07-30 | Anti-activin a antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201729T1 true HRP20201729T1 (hr) | 2020-12-25 |
Family
ID=52427866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201729TT HRP20201729T1 (hr) | 2013-07-30 | 2020-10-27 | Antitijela protiv aktivina a i njihova primjena |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US9718881B2 (hr) |
| EP (4) | EP3730151A1 (hr) |
| JP (5) | JP6581085B2 (hr) |
| KR (2) | KR102440044B1 (hr) |
| CN (2) | CN113845594A (hr) |
| AU (2) | AU2014296243B2 (hr) |
| BR (1) | BR112016002164B1 (hr) |
| CA (1) | CA2920071C (hr) |
| CL (1) | CL2016000251A1 (hr) |
| CY (1) | CY1123788T1 (hr) |
| DK (1) | DK3027209T3 (hr) |
| EA (1) | EA037926B1 (hr) |
| ES (1) | ES2827673T3 (hr) |
| HK (1) | HK1225322A1 (hr) |
| HR (1) | HRP20201729T1 (hr) |
| HU (1) | HUE052518T2 (hr) |
| IL (2) | IL243822B (hr) |
| LT (1) | LT3027209T (hr) |
| MX (2) | MX371498B (hr) |
| PH (1) | PH12016500182A1 (hr) |
| PT (1) | PT3027209T (hr) |
| RS (1) | RS61124B1 (hr) |
| SG (1) | SG11201600731WA (hr) |
| SI (1) | SI3027209T1 (hr) |
| TW (2) | TW201920262A (hr) |
| UY (1) | UY35682A (hr) |
| WO (1) | WO2015017576A1 (hr) |
| ZA (1) | ZA201601294B (hr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2631013C (en) | 2005-11-23 | 2019-06-11 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| ES2415666T3 (es) | 2007-02-01 | 2013-07-26 | Acceleron Pharma, Inc. | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| CN101687016B (zh) | 2007-02-09 | 2014-12-31 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途 |
| US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| AU2010322011B2 (en) | 2009-11-17 | 2016-03-31 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| MX2016016531A (es) | 2014-06-13 | 2017-04-25 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de las ulceras. |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| EA039118B1 (ru) * | 2015-04-01 | 2021-12-07 | Ридженерон Фармасьютикалз, Инк. | Способ лечения прогрессирующей оссифицирующей фибродисплазии |
| CN107771081A (zh) | 2015-04-15 | 2018-03-06 | 瑞泽恩制药公司 | 用gdf8抑制剂增加力量和功能的方法 |
| WO2016176341A1 (en) | 2015-04-29 | 2016-11-03 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| TWI824372B (zh) * | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2018009732A1 (en) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| AU2017340504A1 (en) * | 2016-10-05 | 2019-04-11 | Acceleron Pharma, Inc. | Compositions and method for treating kidney disease |
| WO2018075378A1 (en) * | 2016-10-17 | 2018-04-26 | Vanderbilt University | Human respiratory syncytial virus antibodies and methods of use therefor |
| JP7139326B2 (ja) * | 2016-11-10 | 2022-09-20 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 |
| DE102018103302A1 (de) * | 2018-02-14 | 2019-08-14 | Noonee Ag | Tragbare Sitzhaltungshilfevorrichtung |
| EA202092064A1 (ru) * | 2018-03-01 | 2020-12-21 | Ридженерон Фармасьютикалз, Инк. | Способы изменения состава тела |
| WO2019241350A1 (en) | 2018-06-13 | 2019-12-19 | Regeneron Pharmaceuticals, Inc. | A rodent model of fibrodysplasia ossificans progressiva |
| KR20210104744A (ko) * | 2018-12-18 | 2021-08-25 | 리제너론 파마슈티칼스 인코포레이티드 | 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법 |
| WO2020243448A1 (en) * | 2019-05-30 | 2020-12-03 | Acceleron Pharma Inc. | Actrii-binding proteins and uses thereof |
| EP4087652A1 (en) | 2020-01-08 | 2022-11-16 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20220140802A (ko) | 2020-02-11 | 2022-10-18 | 리제너론 파아마슈티컬스, 인크. | 항-acvr1 항체 및 이의 용도 |
| US20210393779A1 (en) | 2020-06-18 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Activin a antibody formulations and methods of use thereof |
| AU2021327238A1 (en) * | 2020-08-20 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists |
| WO2023022968A2 (en) * | 2021-08-16 | 2023-02-23 | Acceleron Pharma Inc. | Compositions and methods for treating renal diseases or conditions |
| CN118451101A (zh) | 2021-10-18 | 2024-08-06 | 百欧麦斯公司 | 抗激活素a抗体、组合物及其用途 |
| WO2023147107A1 (en) * | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
| WO2023154672A2 (en) * | 2022-02-14 | 2023-08-17 | Ohio University | Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions |
| TWI819587B (zh) * | 2022-04-29 | 2023-10-21 | 洪慧妤 | 用於預防癌症所引發的肌少症之組合物及組合物於製造供預防癌症所引發之肌少症食品的用途 |
| US20240199728A1 (en) | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| EP1075272B1 (en) | 1998-05-06 | 2009-07-15 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
| TR200400621T2 (tr) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| MXPA05012965A (es) | 2003-06-02 | 2006-03-09 | Wyeth Corp | Uso de inhibidores de miostatina (gdf8) en conjuncion con corticoesteroides para el tratamiento de desordenes neuromusculares y composiciones farmaceuticas para ello. |
| JP2007535912A (ja) | 2003-12-31 | 2007-12-13 | シェーリング−プラウ・リミテッド | 中和エピトープベースの増殖増強性ワクチン |
| WO2005084699A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| EA014112B1 (ru) | 2004-03-23 | 2010-10-29 | Эли Лилли Энд Компани | Моноклональное антитело к миостатину и способы его применения |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| EP1778275A2 (en) | 2004-08-12 | 2007-05-02 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US7807159B2 (en) | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
| SI1915397T1 (sl) | 2005-08-19 | 2015-05-29 | Wyeth Llc | Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8 |
| CN101277976B (zh) | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| UA98447C2 (ru) * | 2005-11-23 | 2012-05-25 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА- ActRIIa И ИХ ПРИМЕНЕНИЕ ДЛЯ СОДЕЙСТВИЯ РОСТУ КОСТЕЙ |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| AU2006321906C1 (en) | 2005-12-06 | 2014-01-16 | Amgen Inc. | Uses of myostatin antagonists |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| MX2009002470A (es) | 2006-09-05 | 2009-03-20 | Lilly Co Eli | Anticuerpos anti-miostatina. |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| PE20090982A1 (es) | 2007-11-05 | 2009-08-13 | Novartis Ag | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| SG171813A1 (en) * | 2008-11-26 | 2011-07-28 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
| MY153078A (en) | 2009-04-27 | 2014-12-31 | Novartis Ag | Compositions and methods for increasing muscle growth |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| AU2010322011B2 (en) | 2009-11-17 | 2016-03-31 | Acceleron Pharma Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| US8871209B2 (en) * | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| GR1007832B (el) | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| PE20150223A1 (es) | 2012-06-15 | 2015-02-11 | Pfizer | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos |
| EP2951205B1 (en) | 2013-02-01 | 2021-08-11 | Santa Maria Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| CN107771081A (zh) | 2015-04-15 | 2018-03-06 | 瑞泽恩制药公司 | 用gdf8抑制剂增加力量和功能的方法 |
| EA202092064A1 (ru) * | 2018-03-01 | 2020-12-21 | Ридженерон Фармасьютикалз, Инк. | Способы изменения состава тела |
-
2014
- 2014-07-28 TW TW107147614A patent/TW201920262A/zh unknown
- 2014-07-28 TW TW103125622A patent/TWI655207B/zh active
- 2014-07-30 AU AU2014296243A patent/AU2014296243B2/en active Active
- 2014-07-30 SG SG11201600731WA patent/SG11201600731WA/en unknown
- 2014-07-30 JP JP2016531870A patent/JP6581085B2/ja active Active
- 2014-07-30 WO PCT/US2014/048957 patent/WO2015017576A1/en active Application Filing
- 2014-07-30 KR KR1020217033330A patent/KR102440044B1/ko active IP Right Grant
- 2014-07-30 CN CN202111054074.XA patent/CN113845594A/zh active Pending
- 2014-07-30 EP EP20176858.7A patent/EP3730151A1/en active Pending
- 2014-07-30 CN CN201480049484.7A patent/CN105592858B/zh active Active
- 2014-07-30 PT PT147504211T patent/PT3027209T/pt unknown
- 2014-07-30 BR BR112016002164-9A patent/BR112016002164B1/pt active IP Right Grant
- 2014-07-30 EA EA201690243A patent/EA037926B1/ru unknown
- 2014-07-30 KR KR1020167005280A patent/KR102315694B1/ko active IP Right Grant
- 2014-07-30 EP EP22171327.4A patent/EP4059520A1/en active Pending
- 2014-07-30 US US14/447,444 patent/US9718881B2/en active Active
- 2014-07-30 MX MX2016001394A patent/MX371498B/es active IP Right Grant
- 2014-07-30 EP EP22171329.0A patent/EP4062937A1/en active Pending
- 2014-07-30 DK DK14750421.1T patent/DK3027209T3/da active
- 2014-07-30 RS RS20201414A patent/RS61124B1/sr unknown
- 2014-07-30 SI SI201431693T patent/SI3027209T1/sl unknown
- 2014-07-30 HU HUE14750421A patent/HUE052518T2/hu unknown
- 2014-07-30 ES ES14750421T patent/ES2827673T3/es active Active
- 2014-07-30 LT LTEP14750421.1T patent/LT3027209T/lt unknown
- 2014-07-30 CA CA2920071A patent/CA2920071C/en active Active
- 2014-07-30 MX MX2020001201A patent/MX2020001201A/es unknown
- 2014-07-30 UY UY35682A patent/UY35682A/es active IP Right Grant
- 2014-07-30 EP EP14750421.1A patent/EP3027209B1/en active Active
-
2016
- 2016-01-25 PH PH12016500182A patent/PH12016500182A1/en unknown
- 2016-01-28 IL IL24382216A patent/IL243822B/en active IP Right Grant
- 2016-01-29 CL CL2016000251A patent/CL2016000251A1/es unknown
- 2016-02-25 ZA ZA2016/01294A patent/ZA201601294B/en unknown
- 2016-12-05 HK HK16113833A patent/HK1225322A1/zh unknown
-
2017
- 2017-06-29 US US15/637,867 patent/US10526403B2/en active Active
-
2019
- 2019-08-28 JP JP2019155139A patent/JP6923602B2/ja active Active
- 2019-10-27 IL IL270218A patent/IL270218B/en active IP Right Grant
-
2020
- 2020-02-07 AU AU2020200892A patent/AU2020200892B2/en active Active
- 2020-07-10 US US16/926,481 patent/US20210163583A1/en not_active Abandoned
- 2020-10-27 HR HRP20201729TT patent/HRP20201729T1/hr unknown
- 2020-12-01 CY CY20201101138T patent/CY1123788T1/el unknown
-
2021
- 2021-07-28 JP JP2021122976A patent/JP7440464B2/ja active Active
-
2022
- 2022-06-29 JP JP2022104218A patent/JP7496387B2/ja active Active
- 2022-08-09 JP JP2022126761A patent/JP2022160619A/ja active Pending
- 2022-11-28 US US18/059,315 patent/US20230312699A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201729T1 (hr) | Antitijela protiv aktivina a i njihova primjena | |
| HRP20161043T1 (hr) | Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2 | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20230844T1 (hr) | Anti-cd3 antitijela, bispecifične molekule koje vežu antigen koji veže cd3 i cd20, i njihove upotrebe | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| JP2016501839A5 (hr) | ||
| HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| HRP20170038T1 (hr) | Protutijela na il-6 i njihova uporaba | |
| JP2011528901A5 (hr) | ||
| HRP20220891T1 (hr) | Protutijela, primjene i postupci | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| MX353931B (es) | Anticuerpos que se unen a ox40 y sus usos. | |
| HRP20210113T1 (hr) | Stabilizirani topljivi prefuzijski rsv f protein za upotrebu u profilaksi rsv infekcije | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| JP2017500018A5 (hr) | ||
| NZ630433A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
| JP2018537421A5 (hr) | ||
| JP2016029056A5 (hr) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2011157378A5 (hr) | ||
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн |